Sen. Bernie Sanders (I-Vt.) debates Sen. Lindsey Graham (R-S.C.) at the Edward M. Kennedy Institute on June 13, 2022 in Boston, Massachusetts. (Photo: Matt Stone/MediaNews Group/Boston Herald via Getty Images)
Jul 26, 2022
Senate Budget Committee Chair Bernie Sanders on Tuesday blasted Democrats' watered-down drug pricing plan and suggested pharmaceutical industry lobbying weakened the proposal.
"It goes nowhere near as far as it should."
"It's a very weak proposal. It goes nowhere near as far as it should," Sanders (I-Vt.) told NBC News' Sahil Kapur.
The deal unveiled earlier this month would enable Medicare to negotiate the prices of a limited number of prescription drugs. Other provisions include creating a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, stopping brand-name manufacturers from blocking generic options, and penalizing companies that raise prices faster than inflation.
The plan is notably backed by Sen. Joe Manchin (D-W.Va.)--who last year blocked a House-approved budget reconciliation package and said this month that he wouldn't support new climate spending or tax hikes on the rich and large corporations.
Sanders, who pushed for a sweeping package last year and has long been a leading Medicare for All advocate, pointed to the U.S. Department of Veterans Affairs (VA) as a model for drug price negotiation.
"The American people want Medicare to negotiate prescription drug prices like the VA does," the senator said Tuesday, according to The Hill.
"The VA has been doing that for decades. The prices they pay are about half as much as Medicare. This thing will only apply to a certain number of drugs," Sanders continued, noting that parts of the proposal would not take effect until 2026.
"So it's a weak proposal. Is it better than nothing? I suppose," he added of Democrats' plan.
\u201cDon't expect Bernie Sanders to scuttle the drug pricing reconciliation bill even though he thinks it's weaker than it should be. I wrote in Feb. 2020 about Bernie's long and secret history as a pragmatic legislator, which contradicts his image as a purist. https://t.co/cB3HodHe6n\u201d— Sahil Kapur (@Sahil Kapur) 1658852042
Sanders also took aim at industry lobbying, specifically calling out the trade group Pharmaceutical Research and Manufacturers of America (PhRMA). As he put it: "We're dealing with the power of PhRMA over the Congress. They don't lose very often."
As Common Dreams reported last week, Big Pharma is mobilizing an army of lobbyists to tank Democrats' drug reform plan while hiking the price of prescription medications.
"Pharma is spending millions to defeat a very modest drug pricing bill," Sanders tweeted Friday. "Joe Manchin, who is blocking climate action, is the major recipient of fossil fuel campaign contributions. This is how a corrupt political system works."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, The U.S. is on a fast track to authoritarianism like nothing I've ever seen. Meanwhile, corporate news outlets are utterly capitulating to Trump, twisting their coverage to avoid drawing his ire while lining up to stuff cash in his pockets. That's why I believe that Common Dreams is doing the best and most consequential reporting that we've ever done. Our small but mighty team is a progressive reporting powerhouse, covering the news every day that the corporate media never will. Our mission has always been simple: To inform. To inspire. And to ignite change for the common good. Now here's the key piece that I want all our readers to understand: None of this would be possible without your financial support. That's not just some fundraising cliche. It's the absolute and literal truth. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. Our Summer Campaign is now underway, and there’s never been a more urgent time for Common Dreams to be as vigilant as possible. Will you donate now to help power the nonprofit, independent reporting of Common Dreams? Thank you for being a vital member of our community. Together, we can keep independent journalism alive when it’s needed most. - Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Senate Budget Committee Chair Bernie Sanders on Tuesday blasted Democrats' watered-down drug pricing plan and suggested pharmaceutical industry lobbying weakened the proposal.
"It goes nowhere near as far as it should."
"It's a very weak proposal. It goes nowhere near as far as it should," Sanders (I-Vt.) told NBC News' Sahil Kapur.
The deal unveiled earlier this month would enable Medicare to negotiate the prices of a limited number of prescription drugs. Other provisions include creating a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, stopping brand-name manufacturers from blocking generic options, and penalizing companies that raise prices faster than inflation.
The plan is notably backed by Sen. Joe Manchin (D-W.Va.)--who last year blocked a House-approved budget reconciliation package and said this month that he wouldn't support new climate spending or tax hikes on the rich and large corporations.
Sanders, who pushed for a sweeping package last year and has long been a leading Medicare for All advocate, pointed to the U.S. Department of Veterans Affairs (VA) as a model for drug price negotiation.
"The American people want Medicare to negotiate prescription drug prices like the VA does," the senator said Tuesday, according to The Hill.
"The VA has been doing that for decades. The prices they pay are about half as much as Medicare. This thing will only apply to a certain number of drugs," Sanders continued, noting that parts of the proposal would not take effect until 2026.
"So it's a weak proposal. Is it better than nothing? I suppose," he added of Democrats' plan.
\u201cDon't expect Bernie Sanders to scuttle the drug pricing reconciliation bill even though he thinks it's weaker than it should be. I wrote in Feb. 2020 about Bernie's long and secret history as a pragmatic legislator, which contradicts his image as a purist. https://t.co/cB3HodHe6n\u201d— Sahil Kapur (@Sahil Kapur) 1658852042
Sanders also took aim at industry lobbying, specifically calling out the trade group Pharmaceutical Research and Manufacturers of America (PhRMA). As he put it: "We're dealing with the power of PhRMA over the Congress. They don't lose very often."
As Common Dreams reported last week, Big Pharma is mobilizing an army of lobbyists to tank Democrats' drug reform plan while hiking the price of prescription medications.
"Pharma is spending millions to defeat a very modest drug pricing bill," Sanders tweeted Friday. "Joe Manchin, who is blocking climate action, is the major recipient of fossil fuel campaign contributions. This is how a corrupt political system works."
From Your Site Articles
Senate Budget Committee Chair Bernie Sanders on Tuesday blasted Democrats' watered-down drug pricing plan and suggested pharmaceutical industry lobbying weakened the proposal.
"It goes nowhere near as far as it should."
"It's a very weak proposal. It goes nowhere near as far as it should," Sanders (I-Vt.) told NBC News' Sahil Kapur.
The deal unveiled earlier this month would enable Medicare to negotiate the prices of a limited number of prescription drugs. Other provisions include creating a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, stopping brand-name manufacturers from blocking generic options, and penalizing companies that raise prices faster than inflation.
The plan is notably backed by Sen. Joe Manchin (D-W.Va.)--who last year blocked a House-approved budget reconciliation package and said this month that he wouldn't support new climate spending or tax hikes on the rich and large corporations.
Sanders, who pushed for a sweeping package last year and has long been a leading Medicare for All advocate, pointed to the U.S. Department of Veterans Affairs (VA) as a model for drug price negotiation.
"The American people want Medicare to negotiate prescription drug prices like the VA does," the senator said Tuesday, according to The Hill.
"The VA has been doing that for decades. The prices they pay are about half as much as Medicare. This thing will only apply to a certain number of drugs," Sanders continued, noting that parts of the proposal would not take effect until 2026.
"So it's a weak proposal. Is it better than nothing? I suppose," he added of Democrats' plan.
\u201cDon't expect Bernie Sanders to scuttle the drug pricing reconciliation bill even though he thinks it's weaker than it should be. I wrote in Feb. 2020 about Bernie's long and secret history as a pragmatic legislator, which contradicts his image as a purist. https://t.co/cB3HodHe6n\u201d— Sahil Kapur (@Sahil Kapur) 1658852042
Sanders also took aim at industry lobbying, specifically calling out the trade group Pharmaceutical Research and Manufacturers of America (PhRMA). As he put it: "We're dealing with the power of PhRMA over the Congress. They don't lose very often."
As Common Dreams reported last week, Big Pharma is mobilizing an army of lobbyists to tank Democrats' drug reform plan while hiking the price of prescription medications.
"Pharma is spending millions to defeat a very modest drug pricing bill," Sanders tweeted Friday. "Joe Manchin, who is blocking climate action, is the major recipient of fossil fuel campaign contributions. This is how a corrupt political system works."
From Your Site Articles
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.